| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Leupin; Peptidase inhibitor 11; PI 11; PI-11; PI11; Protease inhibitor (leucine serpin); SCCA 2; SCCA-2; SCCA1; SCCA2; SCCA2/SCCA1 fusion protein; Serine (or cysteine) proteinase inhibitor; clade B (ovalbumin); member 4; Serpin B4; Serpin peptidase inhibitor; clade B (ovalbumin); member 4; SERPINB 4; SERPINB4; SPB4_HUMAN; Squamous cell carcinoma antigen 1; Squamous cell carcinoma antigen 2 |
| Clonality | |
| Conjugate | |
| Form | Liquid |
| Host | |
| Immunogen | Recombinant Human Serpin B4 protein (128-208AA) |
| Isotype | |
| Product Type | |
| Reactivity | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Storage | |
| Target | |
| UniProt # |
Overview
This polyclonal anti-SERPINB4 antibody raised in Rabbit, tested in ELISA, IHC, IF. Designed to detect SERPINB4 in Human for immunology research.
Key elements and design rationale
- Immunogen: Recombinant Human Serpin B4 protein (128-208AA) — determines epitope; confirm sample prep compatibility.
- Host (Rabbit): Requires anti-rabbit-IgG secondary matching isotype IgG.
- Polyclonal: Multiple epitopes = robust signal; lot-to-lot variability — include controls.
- Isotype (IgG): Match secondary, Protein A/G, and isotype controls to IgG.
- Purification (Protein G purification): Enriches Ig classes; reduces non-specific background.
Biological background
SERPINB4 (also: Leupin, Peptidase inhibitor 11, PI 11, PI-11, PI11, Protease inhibitor (leucine serpin), SCCA 2, SCCA-2, SCCA1, SCCA2, SCCA2/SCCA1 fusion protein, Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 4, Serpin B4, Serpin peptidase inhibitor, clade B (ovalbumin), member 4, SERPINB 4, SERPINB4, SPB4_HUMAN, Squamous cell carcinoma antigen 1, Squamous cell carcinoma antigen 2) — studied in Human systems. Expression, localization, and PTMs vary across cell types and disease states. Consult UniProt, NCBI Gene, and primary literature for current SERPINB4 annotation relevant to immunology.
Common research applications
- ELISA: Quantify soluble target; ensure samples within the linear detection range.
- IHC: Tissue expression in FFPE/frozen sections; optimize antigen retrieval.
- IF: Subcellular localization in fixed cells/sections; optimize fixation.
Notes for experimental interpretation
- Isotype controls: IgG from Rabbit at equivalent concentration.
- Cross-reactivity: Polyclonal: validate with KO/KD controls.
- Matrix effects: Verify dilution linearity in your sample matrix.
- Reactivity: Confirmed for Human; extrapolation requires validation.
This product is a polyclonal antibody purified from rabbit antiserum.
SERPINB4 is a protein studied in Human biology. This polyclonal antibody raised in Rabbit detects SERPINB4 in ELISA, IHC, IF applications, IgG isotype.
Reported reactive against Human. Immunogen from Human. Cross-reactivity with untested species requires empirical confirmation.
Reported for ELISA, IHC, IF. Optimize dilution/blocking per application. Consult datasheet for working concentrations.
Non-conjugated IgG; requires anti-rabbit-IgG secondary conjugated to your preferred reporter (HRP, AP, fluorophore, or biotin).
(1) Isotype control: IgG from Rabbit; (2) Positive control: lysate/cell line expressing SERPINB4; (3) Negative control: siRNA KD or KO; (4) Dilution linearity in your sample matrix.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
